Healthcare: 19 A-Grades, Six Insurance Disasters

The Split That Defines Healthcare

Healthcare earned 19 A-grades across 29 companies. That's a 66% A-grade rate, higher than tech, higher than industrials, higher than almost everything except REITs. The sector median FCF margin sits at 16.1%. Nineteen companies are on improving trends.

Then you look at the bottom five and realize this sector has two completely different businesses wearing the same label.

Gilead, AbbVie, Bristol-Myers: 29.1%, 27.6%, 25.5% FCF margins. All A-grades. Pharma prints cash like it's the core competency.

UnitedHealth, Cigna, CVS, Elevance, Humana: 3.4%, 3.1%, 1.8%, 1.5%, 0.1%. Five F-grades. Health insurance generates revenue at scale but converts almost none of it to free cash flow.

The margin gap between the top five and bottom five is 28 percentage points. That's not variance. That's two industries pretending to be one sector.

Why Pharma Works

The top five FCF performers are all pharma or animal health (Zoetis). These aren't growth narratives or pipeline stories. These are companies that already own blockbuster drugs, have pricing power, and convert revenue to cash with minimal friction.

Gilead at 29.1% isn't an outlier. It's the natural state of a profitable pharma company with mature products. Same for AbbVie at 27.6%, riding Humira's tail and Rinvoq's ramp. Bristol-Myers at 25.5% despite a declining trend still clears the A-grade threshold by 10 points.

Zoetis and IDEXX round out the top five. Animal health doesn't get the headlines human pharma does, but the fundamentals are identical: high-margin products, sticky customer bases, limited capital intensity. Zoetis posts 23.2%, IDEXX 22.9%. Both A-grades.

The trend breakdown here matters. Gilead, AbbVie, and IDEXX are all improving. Bristol-Myers and Zoetis are declining but still so far above the A-grade threshold (15% for healthcare) that the trend hasn't hurt the grade yet. When your base margin is 25%, you can afford some slippage.

Medical Devices Hold Strong

Devices occupy the middle of the pack, and most of them grade well. Intuitive Surgical (16.9%), Stryker (16.1%), Boston Scientific (15.5%), Abbott (15.2%). All A-grades. All either stable or improving.

Devices have higher capital needs than pharma but still convert cash efficiently once scale is reached. Intuitive owns robotic surgery. Stryker owns orthopedics. Boston Scientific owns interventional cardiology. These aren't commodity markets. They're oligopolies with pricing power and high switching costs.

The sector's 7.6x average debt-to-FCF ratio is elevated but manageable. Some of that debt sits with companies like Danaher (20.2% margin, A-grade) and Thermo Fisher (13.4%, A-grade) that use leverage to fund acquisitions. Both are on stable or improving trends. The debt load hasn't triggered downgrades because the cash flow covers it.

The Insurance Problem

When we last looked at healthcare in June, the insurance disaster was already visible. It's worse now.

UnitedHealth: 3.4% FCF margin, F-grade, improving trend. The improving trend sounds good until you realize it's improving from catastrophic to merely terrible. A 3.4% margin in a sector where the median is 16.1% isn't competitive. It's structural.

Cigna: 3.1%, F-grade, declining. CVS: 1.8%, F-grade, declining. Elevance: 1.5%, F-grade, improving. Humana: 0.1%, F-grade, improving.

Five F-grades. All major health insurers. Combined, these companies generate hundreds of billions in revenue. They convert almost none of it to free cash flow.

The issue isn't revenue growth. The issue is that health insurance operates on razor-thin underwriting margins, burns cash on claims management and provider negotiations, and faces constant regulatory pressure on pricing. Revenue scales, but so do costs. Free cash flow doesn't follow.

Three of the five insurers are on improving trends, but improving from 0.1% to maybe 2% doesn't fix the fundamental problem. These companies will never grade well under a cash flow framework unless the business model changes.

Moderna's Outlier Status

Moderna at -133.1% deserves its own paragraph. The company is burning cash faster than it generates revenue. That's an F-grade with no modifiers that could save it.

The improving trend means the burn rate is slowing, but slowing from -133% to maybe -80% is not a victory. Moderna rode the COVID vaccine wave to massive 2021-2022 cash flow, then crashed when demand normalized. The current state is post-boom reality: high R&D costs, low commercial revenue, negative free cash flow.

Unless the pipeline delivers another blockbuster, Moderna stays in F territory. The market knows this. The Aureus grade just makes it explicit.

What the Trends Reveal

Nineteen improving trends out of 29 companies. Four stable. Six declining.

The improving trends cluster in pharma (Gilead, AbbVie, Merck, Biogen, Amgen) and devices (Intuitive, Stryker, IDEXX, DexCom, Illumina). The companies that already had strong margins are getting stronger.

The declining trends split between legacy pharma facing patent cliffs (Bristol-Myers, J&J) and insurers losing ground (Cigna, CVS). Boston Scientific is the only major device company declining, and it still holds a 15.5% margin with an A-grade.

The sector's health depends entirely on which subsector you're evaluating. Pharma and devices: excellent. Insurance: structural disaster. Biotech: mostly solid except for Moderna's outlier burn.

The Sector That Isn't One

Healthcare's 66% A-grade rate looks strong until you realize it's propped up by pharma and devices while insurance drags the bottom. The 16.1% median margin hides a 28-point spread between top and bottom performers.

If you split healthcare into "drug and device companies" and "health insurers," you'd have one sector with a 20%+ median margin and another with a 2% median margin. The current structure masks that reality.

Nineteen A-grades is impressive. Six F-grades, five of which are the largest insurers in the country, is a problem the sector can't solve without fundamental business model changes.

Pharma prints cash. Devices print cash. Insurance doesn't. That's the healthcare sector in three sentences.